摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-氟-1H-吲唑 | 341-24-2

中文名称
7-氟-1H-吲唑
中文别名
7-氟吲唑
英文名称
7-fluoro-1H-indazole
英文别名
——
7-氟-1H-吲唑化学式
CAS
341-24-2
化学式
C7H5FN2
mdl
MFCD09026976
分子量
136.129
InChiKey
FQNFMARSNKXCAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    120 °C (decomp)
  • 沸点:
    274.9±13.0 °C(Predicted)
  • 密度:
    1.370±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:625f8a0838b4beab59fcf816efa4ac8b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 7-Fluoro-1h-indazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 7-Fluoro-1h-indazole
CAS number: 341-24-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5FN2
Molecular weight: 136.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

7-氟-1H-吲唑是一种杂环有机物,可用作医药中间体。

制备

以2-氟-6-甲基苯胺为起始原料合成7-氟-1H-吲唑的方法,原料易得、条件温和、操作简单且收率较高。这为7-氟-1H-吲唑类化合物的合成及研究提供了有价值的参考。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-氟-1H-吲唑盐酸 、 sodium hydride 作用下, 以 四氢呋喃 、 mineral oil 为溶剂, 反应 6.25h, 生成 7-fluoro-1-((4,5-dihydro-1H-imidazol-2-yl)methyl)-1H-indazole hydrochloride
    参考文献:
    名称:
    Synthesis and biological activities of 2-[(heteroaryl)methyl]imidazolines
    摘要:
    A series of 2-[(heteroaryl)methyl]imidazolines was synthesized and tested for their activities at alpha(1)- and alpha(2)-adrenoceptors and imidazoline I(1) and I(2) receptors. The most active 2-[(indazol-1-yl)methyl]imidazolines showed high or moderate affinities for alpha(1)- and alpha(2)-adrenoceptors. However, their intrinsic activities at alpha(2A)-adrenoceptors proved to be negligible. A selected 7-chloro derivative behaved as a potent alpha(1)-adrenoceptor antagonist and exhibited peripherally mediated hypotensive effects in rats. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.11.025
  • 作为产物:
    描述:
    2,3-二氟苯乙酮一水合肼 作用下, 以41%的产率得到7-氟-1H-吲唑
    参考文献:
    名称:
    Fluorinated analogues of marsanidine, a highly α2-AR/imidazoline I1 binding site-selective hypotensive agent. Synthesis and biological activities
    摘要:
    The aim of these studies was to establish the influence of fluorination of the indazole ring on the pharmacological properties of two selective alpha(2)-aradrenoceptor (alpha(2)-AR) agonists: 1-[(imidazolidin-2-yl) imino]-1H-indazole (marsanidine, A) and its methylene analogue 1-[(4,5-dihydro-1H-imidazol-2-yl) methyl]-1H-indazole (B). Introduction of fluorine into the indazole ring of A and B reduced both binding affinity and alpha(2)-AR/I-1 imidazoline binding site selectivity. The most alpha(2)-AR-selective ligands were 6-fluoro-1-[(imidazolidin-2-yl)imino]-1H-indazole (6c) and 7-fluoro-1-[(imidazolidin-2-yl)imino]-1H-indazole (6d). The in vivo cardiovascular properties of fluorinated derivatives of A and B revealed that in both cases the C-7 fluorination leads to compounds with the highest hypotensive and bradycardic activities. The alpha(2)-AR partial agonist 6c was prepared as a potential lead compound for development of a radiotracer for PET imaging of brain alpha(2)-ARs. (C) 2014 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2014.09.083
点击查看最新优质反应信息

文献信息

  • [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
    申请人:DAINIPPON SUMITOMO PHARMA CO
    公开号:WO2012169649A1
    公开(公告)日:2012-12-13
    The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]
    本发明涉及一种新型吲唑基或吡咯吡啶基衍生物,由下面的式(1)表示,该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用,并且包括含有该衍生物的药物组合物。式(1)[其中每个取代基如权利要求1所定义]
  • Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    申请人:Molino F. Bruce
    公开号:US20060052378A1
    公开(公告)日:2006-03-09
    The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R 14 ; with R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 14 defined herein.
    本发明的化合物由以下式中的化学结构表示(I): 其中: 指定为*的碳原子处于R或S构型;X是从苯并呋喃基、苯并噻吩基、苯并异噻唑基、苯并异噁唑基、吲哚基、吲哚基、异吲哚基、吲哚啉基、苯并咪唑基、苯并噁唑基、苯并噻唑基、苯并三唑基、咪唑并[1,2-a]吡啶基、吡唑并[1,5-a]吡啶基、[1,2,4]三唑并[4,3-a]吡啶基、噻吩并[2,3-b]吡啶基、噻吩并[3,2-b]吡啶基、1H-吡咯并[2,3-b]吡啶基、茚基、茚基、二氢苯并环庚烯基、四氢苯并环庚烯基、二氢苯并噻吩基、二氢苯并呋喃基、吲啉基、萘基、四氢萘基、喹啉基、异喹啉基、4H-喹啉基、9aH-喹啉基、喹唑啉基、喜啉基、邻苯二嗪基、喹啉基、苯并[1,2,3]三嗪基、苯并[1,2,4]三嗪基、2H-香豆素基、4H-香豆素基或者是一个可选地用取代基(1至4个)取代的螺联苯环或螺联杂环的螺联双环碳环或螺联双环杂环; 其中R1、R2、R3、R4、R5、R6、R7、R8和R14在此处定义。
  • [EN] RORGAMMAT INHIBITORS<br/>[FR] INHIBITEURS DE RORGAMMAT
    申请人:MERCK SHARP & DOHME
    公开号:WO2012106995A1
    公开(公告)日:2012-08-16
    The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    本发明涉及按照式(I)的化合物或其药用可接受的盐或溶剂。这些化合物可用于治疗RORgammaT介导的疾病或症状。
  • PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
    申请人:Andrews Mark David
    公开号:US20120258950A1
    公开(公告)日:2012-10-11
    The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    本发明涉及式(I)化合物及其药学上可接受的盐,其中取代基如本文所述,并且它们在医学上的用途,特别是作为Trk拮抗剂。
  • INHIBITORS OF CAMKK2 AND USES OF SAME
    申请人:New York University
    公开号:US20200369656A1
    公开(公告)日:2020-11-26
    The present disclosure provides compounds suitable for inhibiting CaMKK2. Also provided are compositions and methods of treating diseases associated with CaMKK2.
    本公开提供适用于抑制CaMKK2的化合物。还提供了与CaMKK2相关疾病的治疗方法和组合物。
查看更多